Navigation Links
Kessler Foundation study provides first Class 1 evidence for cognitive rehabilitation in MS
Date:11/21/2013

WEST ORANGE, NJ November 21, 2013. Kessler Foundation researchers published the results of the MEMREHAB Trial in Neurology, the medical journal of the American Academy of Neurology, providing the first Class I evidence for the efficacy of cognitive rehabilitation in multiple sclerosis (MS). The article, Chiaravalloti N, Moore NB, Nikelshpur OM, DeLuca D: An RCT to treat learning impairment in MS. Neurology 2013(81), was released as an epub ahead of print on November 8. It was accompanied by an editorial: Filippi M, Rocca MA: Let's rehabilitate cognitive rehabilitation for MS. Neurology 2013(81):1-2.

Although disabling cognitive problems that affect functional performance and employment are common in persons with MS, there are very few evidence-based protocols for cognitive rehabilitation in MS. This randomized controlled trial (RCT) is the first to include both objective (investigator administered) and subjective measures (patient and family self-report). Investigators looked at the impact of the modified Story Memory Technique (mSMT) on learning and memory in 86 participants with MS with documented memory deficits (41 mSMT group, 45 placebo). Not only did objective measures improve, patients and families reported improvements in daily function in everyday life - improvements that had a positive impact on satisfaction with life and everyday contentment.

"Our results show that cognitive rehabilitation works," said Nancy Chiaravalloti, Ph.D., director of Neuroscience & Neuropsychology Research at Kessler Foundation, "and moreover, the effects of the 10-session protocol persisted for six months." a unique aspect of the protocol is the inclusion of 2 sessions that focus on translating cognitive strategies to daily life. Neuroimaging results that were collected in a subset of patients were published in the Journal of Neurology in 2012 (Chiaravalloti N, et al. Increased cerebral activation after behavioral treatment for memory deficits in MS. J Neurol 2012;259:1337-46). FMRI supported the clinical results, as evidenced by changes in brain activation, noted Dr. Chiaravalloti.

The two studies are being used to support reimbursement for cognitive rehabilitation. "RCTs are essential to demonstrating to third party payers that cognitive rehabilitation should be a reimbursable intervention," commented John DeLuca, Ph.D., VP of Research & Training at Kessler Foundation. "Behavioral intervention should be available for persons with MS who have memory deficits. Without reimbursement, however, few clinicians will use it and few patients will benefit."

The mSMT protocol has been translated into Spanish and is being used in the U.S., Mexico, and Argentina. A Chinese translation has also been completed for use in upcoming studies. Future studies will consider other factors such as type of MS, the duration of MS, and level of cognitive reserve.


'/>"/>

Contact: Carolann Murphy
CMurphy@kesslerfoundaiton.org
973-324-8382
Kessler Foundation
Source:Eurekalert

Related medicine news :

1. Kessler researchers find aerobic exercise benefits memory in persons with multiple sclerosis
2. Kessler Foundation researcher reports pilot results from a virtual reality executive function task
3. Kessler Foundation fellow receives grant from National Institutes of Health
4. Kessler Foundation awarded more than $500,000 in grants by NJ Commission on Brain Injury Research
5. Kessler Foundations Elaine Katz presents at national summit on disability employment
6. Kessler Foundation participates in multi-site NIH study to develop caregiver TBI-CareQOL
7. Kessler Foundations James Sumowski, Ph.D., speaks at April 18-19 MS Symposium in Toronto
8. Dr. DeLuca of Kessler Foundation speaks at Consortium of MS Centers meeting in Chicago
9. Kessler Foundation scientists receive Consortium of MS Centers grant to study emotional processing
10. Kessler Foundation scientist receives National MS Society grant for predictors of memory decline
11. Kessler Foundation scientist receives National MS Society grant for new memory study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2019)... ... August 21, 2019 , ... ... Crossroads Hospice & Palliative Care’s Veterans and First Responders Recognition Ceremony on Wednesday, ... area residents representing all branches of the military and law enforcement are expected ...
(Date:8/21/2019)... , ... August 21, 2019 , ... ... Retriever mascot from Morgantown, Pennsylvania, a lovable, socially popular, registered therapy dog, ... 22 called Never Bean Better Day. The Registrar at National Day Calendar has ...
(Date:8/21/2019)... ... ... ISOComforter , a leader in providing products for cold therapy pain relief , has ... cold unit supply that is shaped like a small cooler. A long tube ... the shoulder pad, lumbar pad, hip wrap, or knee pad. , ISOComforter has changed and ...
(Date:8/21/2019)... PITTSBURGH (PRWEB) , ... August 21, 2019 , ... ... at Providence Point on Sunday, July 28. The Phase II expansion of Providence ... Providence Point campus, as well as construction of the 70-unit apartment tower, Hamilton ...
(Date:8/19/2019)... ... August 19, 2019 , ... ... Eminence Organic Skin Care products , the authorized retailer will change its corporate ... a practicing esthetician in Florida providing Eminence Organic Skin Care facials and treatments. ...
Breaking Medicine News(10 mins):
(Date:8/16/2019)... ... August 16, 2019 , ... A new medical device for ... that both corrects the curve and maintains flexibility in the spine. , The ... by medical staff of Shriners Hospitals for Children® — Philadelphia. It is the ...
(Date:8/16/2019)... ... August 16, 2019 , ... ... that could potentially treat treatment-resistant hypertension by acting in the brain to interfere ... million people worldwide that are affected by treatment-resistant hypertension, resulting in almost 10 ...
(Date:8/16/2019)... (PRWEB) , ... August 16, 2019 , ... ... and Eastern Europe since 2005, announced it has successfully completed enrollment of 690 ... dysfunction. This is a dose ranging, multicenter, randomized, double-blind, placebo-controlled, home use, parallel ...
Breaking Medicine Technology: